P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
I. Breitkreutz,Marc-Steffen Raab,Sonia Vallet,Teru Hideshima,Noopur Raje,Constantine Mitsiades,D Chauhan,Yutaka Okawa,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +10 more
TL;DR: It is concluded that both agents specifically target key factors in osteoclastogenesis, and could directly affect the MM-OCL-BMSCs activation loop in osteolytic bone disease.
Journal ArticleDOI
Clinically relevant end points and new drug approvals for myeloma.
Kenneth C. Anderson,Robert A. Kyle,S V Rajkumar,Alexander Keith Stewart,Donna M. Weber,Paul G. Richardson +5 more
TL;DR: This manuscript summarizes the recommendations of the American Society of Hematology/US Food and Drug Administration Workshop on Clinical Endpoints in Multiple Myeloma to provide the framework for the design of appropriate clinical trial strategies for more rapid new drug approval in myeloma.
Journal ArticleDOI
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
Gullu Gorgun,Elisabetta Calabrese,Ender Soydan,Teru Hideshima,Giulia Perrone,Madhavi Bandi,Diana Cirstea,Loredana Santo,Yiguo Hu,Yu-Tzu Tai,Sabikun Nahar,Naoya Mimura,Claire Fabre,Noopur Raje,Nikhil C. Munshi,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +17 more
TL;DR: It is demonstrated that modulation of SOCS1 may enhance immune response and efficacy of IMiDs in MM and the mechanism of inhibitory-cytokine signaling in effector cells and MM cells is defined.
Journal ArticleDOI
Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
Andrzej Jakubowiak,Don M. Benson,William I. Bensinger,David S. Siegel,Todd M. Zimmerman,Ann Mohrbacher,Paul G. Richardson,Daniel E. H. Afar,Anil K. Singhal,Kenneth C. Anderson +9 more
TL;DR: The combination of elotuzumab and bortezomib was generally well-tolerated and showed encouraging activity in patients with relapsed/refractory multiple myeloma.
Journal ArticleDOI
PI3K/p110δ is a novel therapeutic target in multiple myeloma
Hiroshi Ikeda,Teru Hideshima,Mariateresa Fulciniti,Giulia Perrone,Naoya Miura,Hiroshi Yasui,Hiroshi Yasui,Yutaka Okawa,Tanyel Kiziltepe,Loredana Santo,Sonia Vallet,Diana Cristea,Elisabetta Calabrese,Gullu Gorgun,Noopur Raje,Paul G. Richardson,Nikhil C. Munshi,Nikhil C. Munshi,Brian J. Lannutti,Kamal D. Puri,Neill A. Giese,Kenneth C. Anderson +21 more
TL;DR: The studies show that PI3K/p110delta is a novel therapeutic target in MM and provide the basis for clinical evaluation of CAL-101 to improve patient outcome in MM.